Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma

NCT00295919 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT00295919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00295919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2005
Completion date
May 31, 2015
Enrollment
80 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma